AlphAIAlphAI — Financial news for AI agents
investing.comSEP 222 min read$AMGN

Amgen stock surges on positive Sjögren’s trial results

Amgen Inc (AMGN) shares rose 4% premarket after positive Phase 3 trial results for dazodalibep in treating Sjögren’s disease. The study met its primary endpoint, showing significant improvement in disease activity. Sjögren’s has no FDA-approved treatments. Adverse events were mild to moderate. Amgen plans to present detailed data at a future medical meeting.

Original reporting
investing.com
Published Sep 22, 2026, 1:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 1:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The trial met its primary endpoint with significant improvement in disease activity, prompting a 4% pre‑market share rise.

02

Market read

First disclosure of pivotal trial success; likely to influence Amgen's valuation and sector sentiment.

03

What to watch

Potential regulatory delays and competition from other CD40L antagonists may temper upside.

Relevance 8/10Novelty 8/10Timing: premarket Tuesday

Background

Amgen announced topline results from its Phase 3 OASIZ 301 study of dazodalibep for Sjögren’s disease, a condition with no approved treatments.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen shares jumped 4% premarket after positive Phase 3 trial results for dazodalibep in Sjögren’s disease.

Expected impact

upward

Evidence & confidence

First report of statistically significant efficacy in a disease with no approved therapy; market reacted with a 4% pre‑market gain.

Market effects

Sector

Biotech sector may see broader rally as successful autoimmune trial boosts confidence in similar programs.

Regional

U.S. biotech stocks could benefit; limited immediate impact on other regions.

Global

Positive data adds to global interest in novel immunology therapies.

Counterpoint

What could challenge this read

If efficacy does not translate to commercial success, the stock could be overvalued after the hype.

Key entities

  • company
    Amgen Inc.

    Biopharma company developing dazodalibep.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 22
$AMGNMedAI 8/10

AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’

Amgen (AMGN) shares rose 4% after reporting positive late-stage trial results for dazodalibep in treating systemic Sjögren’s disease, a condition with no approved therapy. The trial showed significant improvement in disease intensity. Citi noted positive results but awaits more details, maintaining a Neutral rating and $405 price target. AMGN is up 25% year-to-date.

stocktwits.com2 min
SEP 22
$AMGNMedAI 8/10

AMGN Looks 10.5% Overvalued on GF Value™ Amid Dividend Sustainab

Amgen (AMGN) reported preliminary positive Phase 3 trial results for dazodalibep, a treatment for systemic Sjogren's syndrome. Citi maintains a Neutral rating with a $405 price target. The stock offers a 2.44% dividend yield, a 44% payout ratio, and a 7.1% 3-year dividend growth rate. GF Value™ suggests the stock is 10.5% overvalued, while the GF Score™ is 86/100, reflecting strong profitability and growth but weaker financial strength and momentum.

gurufocus.com2 min
SEP 22
$AMGNMedAI 9/10

Amgen’s dazodalibep meets primary endpoint in Sjögren’s trial

Amgen (AMGN) reported that its Phase 3 trial of dazodalibep met the primary endpoint in treating Sjögren’s disease, showing significant improvement at Week 48. The study enrolled 621 patients. Dazodalibep is not yet FDA-approved. Amgen plans to share detailed data at a future medical meeting. The company's Phase 3 OASIZ 303 study is expected to complete in Q4 2026.

investing.com2 min
SEP 22
$AMGNHighAI 8/10

Why is Amgen stock surging today?

Amgen (AMGN) stock rose 3.5% after its Phase 3 OASIZ 301 study of dazodalibep met primary endpoints, showing improvement in systemic Sjögren’s disease. Analysts maintained varied ratings. The broader market saw modest gains.

investing.com2 min
SEP 22
$AMGNHighAI 8/10

Amgen’s dazodalibep Phase 3 trial clears Sjögren’s hurdle

Amgen (AMGN) reported that its Phase 3 trial for dazodalibep met its primary endpoint in treating moderate-to-severe systemic Sjögren’s disease, showing statistically significant improvement. The study enrolled 651 participants, and the drug is currently under review. Amgen's revenue was $10.054 billion in Q2 2026, with net income of $2.375 billion. A second Phase 3 trial, OASIZ 303, is expected to complete in Q4 2026.

financial-news.co.uk2 min